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Study Objective. To investigate oseltamivir and oseltamivir carboxylate phar-
macokinetics in critically ill patients who were receiving continuous veno-
venous hemodialysis (CVVHD) and/or extracorporeal membrane
oxygenation (ECMO).
Design. Prospective, open-label, pharmacokinetic study.
Setting. Intensive care units of an academic medical center.
Patients. Thirteen critically ill patients aged 13 years or older with suspected
or confirmed H1N1 influenza who had a prescription for oseltamivir and
were concurrently receiving CVVHD and/or ECMO between October 2009
and January 2010.
Intervention.Oseltamivir 150 mg was administered nasogastrically or na-
soenterically every 12 hours. Blood samples were collected at baseline and
at 1, 2, 4, 6, 8, 10, and 12 hours after administration of the fourth osel-
tamivir dose or subsequent doses. In patients receiving CVVHD, effluent
also was collected at the same time points. Urine was collected throughout
the 12-hour dosing interval.
Measurements and Main Results. Eight patients received CVVHD only, four
patients received both CVVHD and ECMO, and one patient received
ECMO only. Pharmacokinetic parameters for the patient who received
only ECMO were not reported. The median maximum plasma concentra-
tion and area under the plasma concentration–time curve for the 12-hour
dosing interval (AUC0–12) for the remaining 12 patients were 83.4 ng/ml
and 216 ng•hour/ml, respectively, for oseltamivir and 2000 ng/ml and
21,500 ng•hour/ml, respectively, for oseltamivir carboxylate. Mean clear-
ance due to CVVHD was 33.8 ml/minute for oseltamivir and 50.2 ml/min-
ute for oseltamivir carboxylate. For patients who received ECMO, no
substantial differences between pre- and post-ECMO oxygenator plasma
concentrations were found for oseltamivir or oseltamivir carboxylate.
Conclusion.Although the optimal pharmacokinetic-pharmacodynamic targets
for oseltamivir carboxylate remain unclear, in the patients receiving
CVVHD with or without ECMO, a regimen of oseltamivir 150 mg every
12 hours yielded a median oseltamivir carboxylate AUC0–12 considerably
higher than would be expected in non–critically ill patients receiving the
same dosage regimen.
Key Words: oseltamivir, oseltamivir carboxylate, critical illness, pharmaco-
kinetics, continuous venovenous hemodialysis, CVVHD, extracorporeal mem-
brane oxygenation, ECMO.
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Oseltamivir, a neuraminidase inhibitor, is
indicated for the prophylaxis and treatment of
influenza A– and B–related illnesses. During the
2009 influenza A H1N1 pandemic, oseltamivir
emerged as a preferred therapy for severe H1N1
infections.1, 2 In cases of severe illness, the
World Health Organization (WHO) recom-
mended higher doses of oseltamivir of up to
150 mg twice/day versus the standard dose of
75 mg twice/day.3 However, this recommenda-
tion was largely empiric, and the pharmacoki-
netics of oseltamivir and its active metabolite,
oseltamivir carboxylate, had not been investi-
gated thoroughly in critically ill patients receiv-
ing continuous renal replacement therapy
(CRRT) and/or extracorporeal membrane oxy-
genation (ECMO). For future influenza pandem-
ics, it will be important to have the disposition
of oseltamivir and oseltamivir carboxylate char-
acterized in critically ill patients requiring CRRT
and/or ECMO therapies.
Oseltamivir is an oral prodrug that is rapidly
converted to oseltamivir carboxylate with
approximately 80% bioavailability in healthy
subjects.4 Because oseltamivir carboxylate has a
low molecular weight of 284.4 Da, is less
than 3% protein bound,4 and is greater
than 99% renally cleared, it is likely that CRRT
would contribute significantly to drug clearance.
Furthermore, it is possible that additional mem-
brane-mediated drug clearance may occur
related to ECMO therapy, as has been shown
with other drugs.5, 6 The purpose of this clinical
investigation was to describe the pharmacokinet-
ics of oseltamivir and oseltamivir carboxylate in
critically ill patients receiving continuous veno-
venous hemodialysis (CVVHD) and/or ECMO.
Methods
Study Design and Patient Population
In this prospective, open-label, pharmacoki-
netic study, patients aged 13 years or older who
were admitted to intensive care units at the Uni-
versity of Michigan (Ann Arbor, MI) with sus-
pected or confirmed H1N1 influenza and who
had a prescription for oseltamivir and were
receiving CVVHD and/or ECMO were included.
Patients were excluded if they had an allergy to
oseltamivir, if they were not expected to com-
plete at least 12 hours of CVVHD and/or ECMO
therapy, or if it was documented that they were
pregnant or breastfeeding.
The institutional review board of the Univer-
sity of Michigan Medical School approved this
study. Informed consent was obtained from each
patient or a legally authorized guardian before
enrollment. Because patients were admitted from
other hospitals and often had varied (and some-
times unavailable) previous oseltamivir dosing
histories, blood samples were collected with the
fourth oseltamivir dose or subsequent doses
received at our hospital.
Pharmacologic Treatment
All patients received oseltamivir 150 mg every
12 hours. Because of their critical illness, none
of these patients were able to take drugs by
mouth, and the commercial oseltamivir suspen-
sion was not available at our institution during
the H1N1 pandemic (the study time frame).
Consequently, for each dose, the powder from
oseltamivir capsules was dissolved in 10–30 ml
of water at room temperature and administered
by nasogastric or postpyloric feeding tube, fol-
lowed by a water flush. Oseltamivir phosphate is
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highly water soluble,7 and a similar administra-
tion technique has been used in other oseltami-
vir studies in critically ill patients.8
Study Procedures
The CVVHD therapy was delivered using a
Prismaflex machine and high-flux polysulfone
Prismaflex HF1000 or HF1400 filters with sur-
face areas 1.1 and 1.4 m2, respectively (Gambro,
Lakewood, CO). In patients receiving CVVHD,
blood samples (4 ml) were obtained from the
CVVHD circuit at the sampling port just before
the hemodialyzer and were collected into gray-
topped, sodium fluoride–ethylenediaminetetra-
acetic acid evacuated blood collection tubes (BD
Diagnostic Systems, Franklin Lakes, NJ) at base-
line and at 1, 2, 4, 6, 8, 10, and 12 hours after
the dose was administered. In addition, effluent
(spent dialysate plus formed ultrafiltrate) sam-
ples (5 ml) were collected at the same time
points from the CVVHD circuit into polypropyl-
ene cryogenic vials. If the patient received
ECMO, blood samples were collected at the
same time points from the ECMO circuit
directly before and after the oxygenator to quan-
tify drug adsorption to the oxygenator mem-
brane. When patients received both CVVHD and
ECMO, CVVHD was performed in parallel with
the ECMO circuit, using a separate dedicated
dialysis access. Both CVVHD and ECMO sam-
pling procedures were followed, except the
ECMO oxygenator samples were limited to the
2- and 12-hour time points. All blood samples
were centrifuged, and the plasma was harvested,
split, and separated into polypropylene cryo-
genic vials. Urine was collected for the 12-hour
dosing interval in all patients who provided
measurable amounts. The total volume was
recorded, and a 5-ml aliquot was taken for anal-
ysis. Plasma, effluent, and urine samples were
stored at 80°C until analysis.
Assays
All samples were shipped on dry ice to be
analyzed at PRA Bioanalytical Laboratory (Assen,
the Netherlands). Oseltamivir and oseltamivir
carboxylate concentrations in plasma, effluent,
and urine samples were determined with liquid
chromatography with tandem mass spectrome-
try. For all three assays, mobile phase A con-
sisted of 0.05% formic acid in methanol-water
(20:80 mixture, volume/volume), and mobile
phase B consisted of 0.05% formic acid in meth-
anol-water (95:5 mixture, volume/volume). Tan-
dem mass spectrometric detection was applied
using an API 5000 (MDS Sciex, Concord, Can-
ada) mass spectrometer operated in positive ion
mode. The data were collected using multiple
reaction monitoring. The selected transitions (m/z)
were 313.20?166.00 or 313.30?166.20 for
oseltamivir, 286.20?138.10 or 286.30?138.10
for oseltamivir carboxylate, 316.20?167.20 or
316.30?167.20 for oseltamivir RO0640796-003-
002 (deuterated internal standard for oseltami-
vir), and 288.20?139.10 or 288.30?139.10 for
RO0640802-004-002 (deuterated internal stan-
dard for oseltamivir carboxylate).
The lower limits of detection for oseltamivir
in plasma, effluent, and urine samples were 1,
0.5, and 5 ng/ml, respectively. The lower limits
of detection for oseltamivir carboxylate were 10,
5, and 30 ng/ml, respectively. Coefficients of
variation were 3.2–8.0% for oseltamivir and 3.4–
7.4% for oseltamivir carboxylate plasma concen-
trations, 1.4–4.5% for oseltamivir and 1.1–2.4%
for oseltamivir carboxylate effluent concentra-
tions, and 1.1–3.9% for oseltamivir and 1.1–
3.1% for oseltamivir carboxylate urine concen-
trations.
Pharmacokinetic Analysis
Patients treated with CVVHD received a pre-
filter citrate infusion for regional anticoagula-
tion.9 Because of this, plasma concentrations
were adjusted to account for plasma dilution
due to the citrate infusion.10 Pharmacokinetic
parameter estimation was performed using non-
compartmental methods. The maximum plasma
concentration during the dosing interval (Cmax)
was determined by observation of the plasma
concentration data. The elimination constant (k)
was calculated by least squares linear regression
of the log-linear portion of the plasma concen-
tration–time curve. Terminal elimination half-life
was calculated as 0.693/k. The area under the
curve for the 12-hour dosing interval (AUC0–12)
and the area under the moment of the plasma
concentration–time curve were calculated using
the linear trapezoidal rule. In two cases when
data points were not available at 12 hours, they
were extrapolated from the decay curve to 12
hours to allow the estimation of AUC0–12. Mean
residence time at steady state (MRTss) was calcu-
lated as the area under the moment of the
plasma concentration–time curve for the dosing
period/AUC0–12.
11 Total clearance (ClT), defined
as ClNR + ClR + ClCVVHD, where ClNR, ClR, and
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ClCVVHD are nonrenal, renal, and CVVHD drug
clearance, respectively, was calculated as dose/
AUC0–12. The steady-state volume of distribution
(Vss) was calculated as MRT • ClT.
12 Because the
dose administered was an oral dose, and bioavail-
ability (F) could not be calculated, ClT and Vss for
oseltamivir are reported as ClT/F and Vss/F.
The saturation coefficient (SA) for oseltamivir
and oseltamivir carboxylate at each time point
was calculated as effluent concentration/prehe-
modialysis filter plasma concentration. The
ClCVVHD was calculated as effluent rate • SA.
The ClR was calculated as (urine drug concen-
tration • total urine volume)/AUC0–12.
13 Creati-
nine clearance was calculated as (urine
creatinine concentration • urine volume)/(serum
creatinine concentration • 12 hrs). Pearson cor-
relation coefficients were calculated to examine
the relationship between ClR and creatinine
clearance. Linear regressions were used to test
the effect of weight or body mass index (BMI)
on pharmacokinetic parameters. A p value of
less than 0.05 indicated a statistically significant
difference when examining the effects of weight
or BMI and administration route on AUC0–12.
Results
Between October 2009 and January 2010, 14
patients were enrolled in the study. Nine
patients received CVVHD only, four received
CVVHD in addition to ECMO, and one patient
received ECMO only. One patient discontinued
CVVHD at 2.5 hours due to clinical improve-
ment and was excluded from the final analysis.
Demographic characteristics of the 13 patients
who completed the trial are presented in
Table 1. Pharmacokinetic parameters for the
patient who received only ECMO were not
reported because the data set did not allow for
the calculation of key pharmacokinetic parame-
ters. No adverse effects related to oseltamivir
treatment were noted in any of the patients dur-
ing the 12-hour study interval. Five (38%) of
the 13 patients were receiving therapy with va-
sopressors (norepinephrine, phenylephrine, or
vasopressin) during the sampling interval. Seven
(54%) of the 13 patients survived until transfer
or discharge from the intensive care unit.
Figure 1 illustrates the oseltamivir and osel-
tamivir carboxylate plasma concentration–time
curves for the 12 patients who received CVVHD
and illustrates the intersubject variability of osel-
tamivir and oseltamivir carboxylate. Median val-
ues and interquartile ranges (IQRs) from the
pharmacokinetic analysis are shown in Table 2.
The median (IQR) AUC0–12 was 216 ng•hour/ml
(156–317 ng•hr/ml) for oseltamivir, and the
median (IQR) AUC0–12 was 21,500 ng•hour/ml
(13,300–34,400 ng•hr/ml) for oseltamivir car-
boxylate for the 12 patients. The median (IQR)
oseltamivir carboxylate concentration at the end













1 F Caucasian Nasogastric 86 35 36.2 Yes Yes
2 M Caucasian Nasogastric 38 16 34.7 No Yes
3 M Caucasian Nasoenteric 65 26 31.8 No No
4 M Caucasian Nasoenteric 68 27 48.7 Yes Yes
5 M Caucasian Nasogastric 87 48 31.5 No No
6 M Caucasian Nasoenteric 86 38 60.8 Yes No
7 F Caucasian Nasoenteric 42 31 38.7 No Yes
8 F African-
American
Nasogastric 55 43 38.2 No Yes
Mean ± SD 65.9 ± 19.7 33.0 ± 10.2 40.1 ± 10.0
Received CVVHD
and ECMO
9 M Caucasian Nasogastric 89 33 24.1 Yes No
10 M Caucasian Nasoenteric 50 31 34.7 Yes No
11 F Caucasian Nasoenteric 45 46 30.0 No Yes
12 M Caucasian Nasogastric 89 45 27.3 No No
Mean ± SD 68.3 ± 24.0 38.8 ± 7.8 29.1 ± 4.5
Received
ECMO only
13 M Caucasian Nasogastric 50 48 30.2 No Yes
APACHE = Acute Physiology and Chronic Health Evaluation; CVVHD = continuous venovenous hemodialysis; ECMO = extracorporeal mem-
brane oxygenation.
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of the dosing interval (12 hrs) was 1760 ng/ml
(1050–2720 ng/ml).
No significant correlation between weight and
AUC0–12 was noted for either oseltamivir or
oseltamivir carboxylate. In addition, no signifi-
cant correlation between BMI and the aforemen-
tioned pharmacokinetic parameters was noted;
however, patients receiving ECMO had substan-
tially smaller BMIs than patients receiving
CVVHD only (Table 1).
In the 12 patients who received CVVHD, the
mean ± SD blood, dialysate, and effluent flow
rates were 196 ± 14.4, 2420 ± 764, and 3300 ±
919 ml/hour (30.8 ± 3.57 ml/kg/hr), respective-
ly. Saturation coefficients were 0.62 ± 0.11 for
oseltamivir and 0.94 ± 0.11 for oseltamivir car-
boxylate. Mean ClCVVHD values were 33.8 ±
9.4 ml/minute for oseltamivir and 50.2 ± 7.0 ml/
minute for oseltamivir carboxylate. For the four
patients who received ECMO, pre- and post-
ECMO oxygenator oseltamivir and oseltamivir
carboxylate concentrations are presented in
Table 3.
Urine samples were collected for 10 of the 13
patients. Of the three patients for whom urine
samples were not available, two did not have a
urinary catheter in place because the patients
were anuric, and one patient’s urine collection
was emptied inadvertently before the 12-hour
interval was completed. The amount of oseltami-
vir (parent or active metabolite) appearing in
the urine was minimal for most patients. A sig-
nificant correlation was noted between oseltami-
vir ClR and calculated creatinine clearance
(r=0.91, p<0.001) as well as oseltamivir carbox-
ylate ClR and calculated creatinine clearance
(r=0.88, p=0.002). The median (IQR) values for
oseltamivir ClR and oseltamivir carboxylate ClR
were 22.53 ml/minute (14.1–52.95 ml/min) and
1.86 ml/minute (0.91–10.83 ml/min), respec-
tively.




CVVHD and ECMO Group
(n=4)
Oseltamivir
Cmax (ng/ml) 103 (75.9–121) 37.3 (30.1–53.8)
C12 (ng/ml) 2.25 (1.48–5.45) 2280 (1310–2840)
Tmax (hrs) 1.0 (1.0–1.3) 1.0 (1.0–1.0)
Vdss/F (L/F) 1460 (1330–2200) 4500 (3760–6990)
ClT/F (L/hr/F) 578 (414–787) 1470 (1020–2570)
Half-life (hrs) 4.1 (3.0–6.8) 4.8 (3.8–8.4)
AUC0–12 (ng•hr/ml) 263 (192–373) 106 (72.5–171)
Oseltamivir carboxylate
Cmax (ng/ml) 2670 (1710–3580) 981 (553–1670)
C12 (ng/ml) 2.50 (0.725–4.63) 727 (300–1430)
Tmax (hrs) 4.0 (4.0–6.5) 7.0 (5.1–8.0)
Half-life (hrs) 22.3 (19.1–33.6) 14.4 (10.1–19.3)
AUC0–12 (ng•hr/ml) 29,500 (17,600–35,800) 9390 (5000–17,600)
Data are median (interquartile range).
CVVHD = continuous venovenous hemodialysis; ECMO = extracorporeal membrane oxygenation; Cmax = maximum concentration during
the dosing interval; C12 = concentration at the end of the 12-hr dosing interval (trough); Tmax = time of maximum concentration; Vdss = vol-
ume of distribution at steady state; F = bioavailability; ClT = total clearance; AUC0–12 = area under the plasma concentration–time curve
from 0–12 hrs.
aPharmacokinetic parameters for the patient who received only ECMO were not reported.
Figure 1. Oseltamivir and oseltamivir carboxylate plasma
concentrations versus time over the 12-hour dosing interval
in the 12 patients who received continuous venovenous
hemodialysis (CVVHD). Closed circles represent patients
receiving CVVHD only, and open squares represent
patients who received both CVVHD and extracorporeal
membrane oxygenation. Lines connecting the data points
are for clarity and were not modeled.
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Discussion
This prospective trial was designed to charac-
terize oseltamivir and oseltamivir carboxylate
pharmacokinetics in patients receiving CVVHD
and/or ECMO. For the 12 patients who received
CVVHD, the mean saturation coefficients of
0.62 ± 0.11 for oseltamivir and 0.94 ± 0.11 for
oseltamivir carboxylate correlate well with the
respective plasma protein binding values of 42%
and 3% reported in healthy volunteers.4 Osel-
tamivir carboxylate freely crossed the CVVHD
membrane, and ClCVVHD was an important route
of elimination in these patients. In the five
patients receiving ECMO, pre- and postoxygena-
tor membrane concentrations of oseltamivir and
oseltamivir carboxylate did not differ substan-
tially (Table 3), suggesting that drug binding to
the oxygenator was not a clinically relevant
source of drug clearance.
In this trial, oseltamivir and oseltamivir car-
boxylate pharmacokinetic parameters exhibited
striking variability. The lowest and highest Cmax
differed by 14-fold for oseltamivir and 18-fold
for oseltamivir carboxylate. Although a substan-
tial portion of the intersubject variability in osel-
tamivir carboxylate concentrations may be due
to differences in the number of previous osel-
tamivir doses, this study also agrees with previ-
ous findings that pharmacokinetic variability can
be increased in critical illness and multiorgan
failure,14 particularly when an oral drug is
administered.15, 16
Many factors may have contributed to the
pharmacokinetic variability seen in these criti-
cally ill patients.14, 17, 18 Administration route
(nasogastric vs nasoenteric) may have contrib-
uted to variability, although there were no sig-
nificant differences in oseltamivir and
oseltamivir carboxylate AUC0–12 between groups
receiving different routes of administration. It is
also possible that oseltamivir could have par-
tially bound to the nasogastric or nasoenteric
tubing. Oseltamivir was administered without
regard to enteral feedings, which all but two
patients (patient nos. 6 and 10) were receiving.
The bioavailability of oseltamivir with enteral
feedings has not been studied, although coad-
ministration of oseltamivir with food does not
significantly affect AUC0–12.
19 A study of the
pharmacokinetics of oseltamivir in critically ill
patients found similar median plasma concentra-
tions in patients receiving and those not receiv-
ing enteral feedings.8
Another contributor to the pharmacokinetic
variability seen in our patients could be due to
variations in the expression and activity of
human carboxylesterase 1, the hepatic enzyme
responsible for the hydrolysis of oseltamivir to
oseltamivir carboxylate. Expression of human
carboxylesterase 1 messenger RNA has been
reported to vary by a factor of 12 in adults,20























9 7 2 8.73 5.92 169 180
12 BLLQ BLLQ 145 200
10 7 2 13.3 12.0 656 726
12 73.3 62.5 351 364
11 5 2 22.1 20.6 987 923
12 5.5 5.7 731 964
12 2 2 65.1 57.6 2860 2740
12 6.9 7.0 2460 2570
ECMO only
13 2 1 9.3 10.5 936 967
2 11.1 11.2 894 967
4 10.6 10.6 908 975
6 13.4 12.3 865 887
8 5.7 7.3 876 853
10 7.0 7.9 1000 896
12 13.2 14.0 913 1050
ECMO = extracorporeal membrane oxygenation; BLLQ = below the lower limit of quantification.
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and genetic polymorphism, proinflammatory
cytokine secretion,21 and drug-drug interac-
tions22 may impair formation of the active
metabolite. However, clinically relevant inhibi-
tion of oseltamivir conversion leading to accu-
mulation of the parent compound is unlikely, as
the oseltamivir carboxylate concentrations were
consistently higher than the oseltamivir concen-
trations for all patients (the oseltamivir carbox-
ylate AUC:oseltamivir AUC ratio ranged from
32–172) (Table 4).
In our patients, variations in oseltamivir and
oseltamivir carboxylate concentrations were
unlikely to be due to drug-drug interactions
because most patients were not receiving poten-
tially interacting drugs. In vitro trials have
reported carboxylesterase 1 inhibition with
tamoxifen, thioridazine, aripiprazole, perphena-
zine, fluoxetine, and certain statin drugs,23, 24
and it is possible that oseltamivir hydrolysis may
be competitively inhibited by other carboxyles-
terase 1 substrates, such as clopidogrel, certain
angiotensin-converting enzyme inhibitors,
meperidine, and methylphenidate.22, 23, 25, 26
The only patient to receive any of these poten-
tially interacting drugs was patient no. 10, who
was receiving fluoxetine. This patient had the
second lowest parent oseltamivir concentrations
of all patients, suggesting that limited conversion
to oseltamivir carboxylate was not a clinically
significant factor in this patient. In addition, no
patients were receiving probenecid, a drug found
to inhibit the tubular excretion of oseltamivir
carboxylate.27
It is not surprising that given the prolonged
half-lives of oseltamivir carboxylate in our
patients (22. 3 hrs in patients receiving CVVHD
only and 14.4 hrs in patients receiving ECMO
and CVVHD), oseltamivir carboxylate exposure
in our study was substantially higher compared
with that expected in healthy volunteers receiving
the same dose.28 Median oseltamivir carboxylate
AUC0–12 values reported in our study were ele-
vated considerably compared with those reported
in a multidose study of healthy volunteers
(21,500 vs 4904 ng•hr/ml),28 suggesting that a
dosage reduction may be warranted from the dos-
age of 150 mg every 12 hours used in our study.
Oseltamivir carboxylate exposure was
decreased compared with another report of osel-
tamivir carboxylate pharmacokinetics in criti-
cally ill adults requiring CRRT.8 That study
evaluated the pharmacokinetics of oseltamivir
and oseltamivir carboxylate in five critically ill
adults who received oseltamivir at standard dos-
ages of 75 mg twice/day. The median oseltamivir
carboxylate AUC0–12 reported for the five
patients (28,023 ng•hr/ml), when doubled to
account for the difference in dosage regimens,
was substantially higher than that found in our
eight patients who received CVVHD without
ECMO (29,500 ng•hr/ml). Although all patients
in both studies had received at least three doses
of oseltamivir before pharmacokinetic sampling
occurred, oseltamivir dosing histories were var-
ied, which may account for some of the differ-
ence. However, the mode of CRRT, effluent rate
used, and degree of residual renal function were
not reported in the other study,8 making a direct
comparison with our study difficult. It may be
that some of the large difference in oseltamivir
carboxylate exposure may be attributed to
increased ClT due to higher CRRT effluent flow
rates (as well as variations in CRRT mode, filter
type, etc.) or greater residual ClR values in our
patients.








1 234 34,900 149
2 492 15,700 32
3 167 24,800 149
4 170 18,200 107
5 333 41,900 126
6 199 34,300 172
7 292 13,400 46
8 553 38,600 70
9 30 2050 68
10 87 5990 69
11 125 12,800 102
12 311 32,200 104
Median (IQR) 216 (156–317) 21,500 (13,300–34,400) 103 (69–131)
AUC = area under the plasma concentration–time curve; IQR = interquartile range.
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Unlike the previous report,8 our study
included patients receiving ECMO. It is worth-
while to note that although pre- and post-ECMO
oxygenator concentrations did not vary consider-
ably, the median oseltamivir carboxylate AUC0–12
for patients receiving both CVVHD and ECMO
(9390 ng/ml•hr) was considerably lower than
that achieved in patients receiving only CVVHD
(29,500 ng/ml•hr). An increased volume of dis-
tribution may have contributed to the decreased
oseltamivir carboxylate exposure as well
(4500 L/F in the CVVHD and ECMO group vs
1460 L/F in the CVVHD-only group). Although
patients receiving ECMO often receive large vol-
umes of blood products that lead to increases in
volume of distribution, this may not fully
explain the more than 3-fold difference in Vss/F
that was observed. Another possible explanation
of the pharmacokinetic variability could be that
oseltamivir exhibited decreased bioavailability in
patients receiving CVVHD and ECMO. Our
ECMO study population was too small to draw
firm conclusions about oseltamivir bioavailabil-
ity. However, an instance of suspected poor oral
oseltamivir bioavailability in a 14-year-old
patient with suspected gastric dysfunction
receiving CRRT and ECMO has been reported in
a case series,29 although the other two patients
in this same series, as well as a patient in a dif-
ferent case report,30 have exhibited much higher
oseltamivir carboxylate concentrations.
Limitations
An important limitation of this study is that
previous oseltamivir dosing history in our
patients varied. Consequently, some of the phar-
macokinetic variability seen with oseltamivir car-
boxylate could have been due to differences in
the number of previous doses received. Because
oseltamivir was administered twice/day, sam-
pling in our trial was limited to a single 12-hour
dosing interval. Oseltamivir carboxylate often
exhibited a half-life longer than the dosing inter-
val itself, making the half-life difficult to charac-
terize. The oral dosage form was not
radiolabeled, preventing us from acquiring infor-
mation about oral bioavailability. Consequently,
volume of distribution and ClT calculations were
affected by oral bioavailability, which is a source
of variability in critically ill patients.16 Finally,
although this study investigated the pharmacoki-
netics of oseltamivir in critically ill patients
receiving CVVHD and/or ECMO, it did not
investigate viral load or clinical outcomes.
Despite these limitations, it remains clear that
the median oseltamivir carboxylate AUC0–12 was
substantially higher than would be expected in
non–critically ill patients administered the same
oseltamivir dose.
Oseltamivir Carboxylate Pharmacodynamics and
Dosing Implications
One study reported a mean ± SD oseltamivir
carboxylate 50% inhibitory concentration (IC50)
of 0.186 ± 0.107 ng/ml for the 2009 H1N1 influ-
enza pandemic.31 The median 12-hour oseltami-
vir carboxylate concentration of 1760 ng/ml
found in our study was more than 9000-fold
higher than this reported IC50, suggesting that a
decrease in dosage is indeed indicated in these
patients. The magnitude of the optimal dosage
decrease is less clear. Although conventional osel-
tamivir dosing appears to yield sufficient drug
exposure to treat influenza infections, the optimal
oseltamivir carboxylate AUC0–24 value has yet to
be derived. Furthermore, human data correlating
oseltamivir carboxylate concentrations in the
plasma with concentrations in the alveolar fluid
have not been established,32 and this correlation
should be clarified to optimize dosing. These
issues, coupled with the large pharmacokinetic
variability seen in our study, make dosing recom-
mendations difficult to make in this population.
Although achieving high oseltamivir plasma
concentrations may lead to adverse effects (e.g.,
nausea, vomiting, neurologic effects),32 oseltami-
vir is well tolerated, and these risks need to be
balanced against the variability of pharmacoki-
netics found in this severely ill population. The
package insert recommends a dosage of 75 mg
once/day for patients with reduced creatinine
clearances of 10–30 ml/minute,19 and this rec-
ommended dosage seems reasonable to apply to
critically ill patients requiring CVVHD at the
effluent rates used in this trial. Centers using
CRRT at higher effluent rates may require more
aggressive dosing. Because the patients in our
study who received ECMO tended to have lower
AUC values, a higher dose might be considered
in these patients, particularly in cases where
gastrointestinal dysfunction is suspected.29
Conclusion
In patients receiving CVVHD, oseltamivir car-
boxylate freely crosses the hemodialysis filter,
and oseltamivir carboxylate clearance from
CVVHD represents an important route of elimi-
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nation in these patients. Use of ECMO does not
appear to contribute substantially to oseltamivir
carboxylate clearance. The oseltamivir carboxyl-
ate AUC0–12 in critically ill patients receiving
CVVHD with or without ECMO was consider-
ably higher than those reported in healthy vol-
unteers. In our critically ill patients receiving
CVVHD, a regimen of oseltamivir 150 mg every
12 hours produced a median oseltamivir carbox-
ylate AUC0–12 substantially higher than would
be expected in non–critically ill patients receiv-
ing the same oseltamivir regimen.
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